Thomas Forest, MD
Urology · Lafayette, LANPI 1760489637
Payments from drug & device makers
Across 24 payments — averaging $33.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$174
- AbbVie$165
- C. R. Bard, Inc. & Subsidiaries$124
- Sumitomo Pharma America, Inc.$98
- Progenics Pharmaceuticals, Inc.$60
- Zyla Life Sciences, Inc.$52
- plus $137 from 6 others
What the payments were for
- Speaking & faculty fees$719%
- Food & beverage$73891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 2 | $174 |
| AbbVie | 8 | $165 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $124 |
| Sumitomo Pharma America, Inc. | 2 | $98 |
| Progenics Pharmaceuticals, Inc. | 2 | $60 |
| Zyla Life Sciences, Inc. | 3 | $52 |
| Novo Nordisk | 1 | $29 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Procept Biorobotics Corporation | 1 | $25 |
| Antares Pharma, Inc. | 1 | $20 |
| Hollister Incorporated | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$809 in reported general payments places this provider in the 20th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxybutynin Chloride ErOxybutynin Chloride | 193 | $2,935 |
| Finasteride | 177 | $2,055 |
| Potassium Citrate ErPotassium Citrate | 67 | $1,904 |
| Tamsulosin Hcl | 190 | $1,706 |
| NitrofurantoinNitrofurantoin Macrocrystal | 34 | $1,404 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 32 | $707 |
| Bicalutamide | 32 | $671 |
| Cefdinir | 40 | $638 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $549 |
| Testosterone Cypionate | 12 | $471 |
| Allopurinol | 45 | $359 |
| Ciprofloxacin Hcl | 30 | $147 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $144 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $56 |
Paid to pharmacies, not to this prescriber.
Other urology in Lafayette
- Thad BourqueLafayette$196K
- William RothLafayette$41K
- Jeffrey ThibodeauxLafayette$8K
- Christopher FontenotLafayette$6K
- Jeremy SpeegLafayette$6K
- Ralph HendersonShreveport$4M
- Kevin ClineShreveport$1.3M
- Nathan FischmanNew Orleans$1.3M
- Ashley BakerShreveport$705K
- Colin GoudelockeNew Orleans$615K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.